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Drugs acting on the central nervous system (CNS) have to cross the blood-brain barrier (BBB) in order 
to perform their pharmacological actions. Passive BBB diffusion can be partially expressed by the blood/
brain partition coefficient (logBB). As the experimental evaluation of logBB is time and cost consuming, 
theoretical methods such as quantitative structure-property relationships (QSPR) can be useful to predict 
logBB values. In this study, a 2D-QSPR approach was applied to a set of 28 drugs acting on the CNS, 
using the logBB property as biological data. The best QSPR model [n = 21, r = 0.94 (r² = 0.88), s = 0.28, 
and Q² = 0.82] presented three molecular descriptors: calculated n-octanol/water partition coefficient 
(ClogP), polar surface area (PSA), and polarizability (α). Six out of the seven compounds from the test 
set were well predicted, which corresponds to good external predictability (85.7%). These findings can 
be helpful to guide future approaches regarding those molecular descriptors which must be considered for 
estimating the logBB property, and also for predicting the BBB crossing ability for molecules structurally 
related to the investigated set.
Uniterms: Two-dimensional quantitative structure-property relationships (2D-QSPR). Calculated 
n-octanol/water partition coefficient (ClogP). Blood-brain barrier. Benzodiazepines.
Fármacos que atuam no sistema nervoso central (SNC) devem atravessar a barreira hematoencefálica 
(BHE) para exercerem suas ações farmacológicas. A difusão passiva através da BHE pode ser parcialmente 
expressa pelo coeficiente de partição entre os compartimentos encefálico e sanguíneo (logBB, brain/blood 
partition coefficient). Considerando-se que a avaliação experimental de logBB é dispendiosa e demorada, 
métodos teóricos como estudos das relações entre estrutura química e propriedade (QSPR, Quantitative 
Structure-Property Relationships) podem ser utilizados na previsão dos valores de logBB. Neste estudo, 
uma abordagem de QSPR-2D foi aplicada a um conjunto de 28 moléculas com ação central, usando 
logBB como propriedade biológica. O melhor modelo de QSPR [n = 21, r = 0,94 (r² = 0,88), s = 0,28 e 
Q² = 0,82] apresentou três descritores moleculares: o coeficiente calculado de partição n-octanol/água 
(ClogP), área de superfície polar (PSA) e polarizabilidade (α). Seis dos sete compostos do conjunto de 
avaliação foram bem previstos pelo modelo, o que corresponde a um bom poder de previsão externa 
(85,7%). Os resultados obtidos podem auxiliar de forma relevante em estudos futuros, orientando quais 
descritores moleculares devem ser considerados para estimar logBB e prever a passagem através da 
BHE de moléculas estruturalmente relacionadas às do conjunto investigado.
Unitermos: Relações quantitativas bidimensionais entre estrutura química e propriedade (2D-QSPR). 
Coeficiente calculado de partição n-octanol/água (ClogP). Barreira hematoencefálica. Benzodiazepínicos. 
INTRODUCTION
The distribution of many drugs to the brain is signifi-
cantly different from that occurring in other organs, owing 
to the presence of the blood-brain barrier (BBB). This 
consists of a specialized system of capillary endothelial 
cells that protects the brain against harmful substances in 
the blood stream, while supplies this organ with the requi-
red nutrients for its proper functions (Escuder-Gilabert et 
al., 2004).
The BBB plays an important role in maintaining ho-
meostasis, separating the brain from systemic circulation. 
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Its endothelial cells have tight junctions, promoting a very 
high transendothelial resistance (1500-2000 Ωcm²), pre-
venting paracellular passage of hydrophilic solutes (Misra 
et al., 2003). Furthermore, a number of neuroanatomical 
structures, including catabolic enzymes, efflux transpor-
ters and astrocytes prolongations, provide a restricted 
diffusion of chemical compounds through the brain (Misra 
et al., 2003; Hitchcock, 2008; Habgood et al., 2000).
Passive diffusion through the BBB is the primary 
process of many therapeutic compounds’ translocation 
from blood to brain. This step is one of the most critical 
pharmacokinetic issues in the designing of drug candi-
dates for action on the Central Nervous System (CNS). 
If the drug cannot cross the BBB, no biological effect in 
the CNS is observed. This penetration is also a concern 
in the development of other classes of drugs, for which 
penetration through the BBB could result in toxicity due 
to undesirable effects on nervous tissues (Li et al., 2005; 
Katritzky et al., 2006). 
Although some drugs use transporters, most of them 
can enter the brain by passive diffusion through the en-
dothelial cells. One of the main important drug properties 
governing passive diffusions is lipophilicity. In general, 
the more lipid soluble the molecule, the more easily it will 
move from the blood to the brain, crossing the endothelial 
cell membranes. Lipophilicity can be expressed by the n-
octanol/water partition coefficient (logP), which represents 
the relative affinity of a molecule between organic and 
aqueous media (Misra et al., 2003; Habgood et al., 2000; 
Goodwin et al., 2005). Other important molecular featu-
res, considering passive diffusion, include molecular size 
(with a cut-off value of 400-700 Da) and intermolecular 
interaction forces (which express the relative affinity to 
lipophilic or hydrophilic solvent) (Habgood et al., 2000; 
Misra et al., 2003; Iyer et al., 2002).
The relative affinity of a molecule between blood 
and brain can be expressed in terms of the blood/brain 
partition coefficient (logBB), according to Equation 1: 
           (1)
In Equation 1, Cbrain and Cblood are the equilibrium 
concentrations of a molecule in the brain and the blood, 
respectively (Katritzky et al., 2006). However, this ex-
perimental determination is time and cost consuming, 
preventing extended applications. Therefore, computer-
assisted drug design methodologies (CADD), such as 
quantitative structure-property and/or structure-activity 
relationship studies (QSPR and QSAR, respectively), 
may help to estimate biological data, reducing synthetic 
steps, predicting pharmacokinetic and pharmacodynamic 
profiles, constituting an important tool in the design and 
development of new drugs and novel leads (Katritzky et 
al., 2006). A literature review reported several studies, 
carried out on a number of different chemical structures, 
and in which 2D and 3D QSPR models have been propo-
sed to predict logBB values (Katritzky et al., 2006; Van 
Damme et al., 2008; Iyer et al., 2002; Konovalov et al., 
2007; Subramanian et al., 2003; Zhao et al., 2007; Zhang 
et al., 2008; Narayanan et al., 2005). Some of these models 
show a correlation between logBB and some physicoche-
mical parameters, such as molecular refractivity (MR), 
molecular volume (V), acid ionization constant (Ka and 
pKa), thermodynamic parameters (solvation energy, etc.), 
polar surface area (PSA), and others. (Chen et al., 2009; 
Clark, 1999). Nevertheless, easy interpretable mathemati-
cal models, with good internal and external predictability, 
are still needed for some specific drug classes. Against this 
background, in the present study a two-dimensional (2D) 
QSPR approach was applied to a set of 28 structurally 
similar molecules including benzodiazepines, tricyclic 
compounds and their metabolites, with CNS activity as 
antidepressant and neuroleptic, in order to build a QSPR 
model able to predict logBB values and also provide 
relevant findings about the BBB crossing ability of other 
compounds structurally related to the investigated set.
MATERIAL AND METHODS
A set of 28 molecules, including benzodiazepines, 
tricyclic compounds and their metabolites, were selected 
from Katritzky et al. (Katritzky el al., 2006). Their structural 
similarity is based on the presence of an azepine or isosteric 
ring bound to at least one aromatic ring. The experimental 
logBB values were assessed using animal models and syn-
thesized radio-labeled compounds. Often, this measure is 
based on the degree of BBB penetration, defined as the ratio 
of the steady-state molar concentration of the drug molecule 
(radio-labeled) in the brain and in the blood (Katritzky et al., 
2006). The logBB values are given in Table 1, comprising 
the dependent variables of this QSPR analysis. The range 
of logBB values is from -1.82 to 1.20.
The molecules were randomly divided into two sets. 
The training set was composed of 21 compounds whereas 
seven compounds were used for the external validation 
(test set). The test set compounds were not included in the 
development of the 2D-QSPR models. 
The three-dimensional structures of each of the 28 
molecules were built in their neutral forms employing the 
HyperChem 7.51 software (Hypercube Inc., 2003). The 
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Compounds Structure logBBexp
1. alprazolam
N
N
Cl
N
N
0.04
2. oxazepam HN
N
Cl
HO
O
0.61
3. midazolam N
N
F
Cl
N
0.36
4. M1-L663-581
N
N
OCl
N
N
ON
OH
-1.34
5. M2-L663-581
N
N
OCl
N
N
ON
OH
OH
-1.82
6. L663-581
N
N
OCl
N
N
ON
-0.30
7. diazepam
N
N
O
Cl
0.52
8. bretazenil
N
N
O
H
N
Br
O
O
-0.09
9. flumazenil
N
N
O
F
N
O
O -0.29
10. Ro 19-4603
N
N
O
S
N
O
O
-0.25
TABLE I - Chemical structures and logBB experimental values (logBBexp) found for training and test sets (Katritzky et al., 2006). 
The test set compounds are marked with an asterisk (*)
Compounds Structure logBBexp
11. demethyldiazepam
N
HN
O
Cl
0.50
12. 1-OH-midazolam N
N
F
Cl
N
HO
-0.07
13. 4-OH-midazolam N
N
F
Cl
N
HO
-0.30
14. triazolam
N
N
Cl
N
N
Cl
0.74
15. clobazam
N
N
O
O
Cl
0.35
16. flunitrazepam N
N
F
NO2O
0.06
17. demethylclobazam
NH
N
O
O
Cl
0.36
18. mianserin N
N
0.99
19. desipramine
N
NH
1.20
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Compounds Structure logBBexp
20. amitriptyline
N
0.98
21. imipramine
N
N
0.83
22. carbamazepine* N
H2N
O
0.00
23. mirtazapine* N
N
N
0.53
24. N-demethyl 
desipramine*
N
H2N
1.06
TABLE I - Chemical structures and logBB experimental values (logBBexp) found for training and test sets (Katritzky et al., 2006). 
The test set compounds are marked with an asterisk (*) (cont.)
Compounds Structure logBBexp
25. ORG4428*
O
N
N
HO H 0.82
26. ORG5222*
O
H H
N
Cl
1.03
27. ORG32104*
O
N
N
H
HO H 0.52
28. ORG30526*
O
H H
N
H
Cl
0.39
crystallized structures of the drugs diazepam and imipra-
mine were retrieved from the Protein Data Bank (PDB) 
(Bernstein et al., 1977) [entry codes 2bxf, resolution 2.95 
Å (Ghuman et al., 2005); and 2q72, resolution 1.70 Å 
(Singh et al., 2007)] and used as the starting geometries 
to construct all benzodiazepines and tricyclic compounds, 
respectively. Each 3D-model had its geometry optimized 
by HyperChem 7.51, using MM+ force field without any 
restriction (Allinger, 1977), followed by the AM1 se-
miempirical quantum method (Dewar et al., 1985). Partial 
atomic charges were calculated using the AM1 semiempi-
rical method, also implemented by the HyperChem 7.51 
program (Hypercube Inc, 2003).
As mentioned above, the structures modeled were 
used to calculate the molecular descriptors or independent 
variables used in this study, employing HyperChem 7.51 
(Hypercube Inc, 2003) and MarvinBeans 4.1.8 software 
(ChemAxon Ltd, 1998-2009) (see Table II).
A preliminary systematic search of the most signifi-
TABLE II - Molecular descriptors calculated using HyperChem® 
7.51 and MarvinBeans 4.1.8 software
Software Molecular Descriptors
HyperChem® 7.51 solvent-accessible surface area 
(Aprox.), solvent-accessible surface 
area (Grid), van der Waals volume, 
solvent-accessible volume.
MarvinBeans 4.1.8 ClogP, polarizability (α), polar surface 
area (PSA), H-bond donor, H-bond 
acceptor, molar refractivity (MR)
cant independent variables was carried out based on their 
distribution or variability against the biological property 
(visual inspections) using scatter plots [Pirouette® 3.11 (In-
fometrix, Inc., 1990-2003)]. Therefore, the scatter plots of 
logBB versus the calculated molecular descriptors aided in 
the decision concerning which molecular descriptors would 
be more relevant in describing the biological property. 
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The selected descriptors were used to build the 
2D-QSPR models employing multiple linear regression 
(MLR) and leave-one-out (LOO) cross-validation method, 
performed by BuildQSAR® 1.0.0 software (Oliveira, 
Gaudio, 2003). Due to the relatively small size of the trai-
ning set (n = 21), the statistical restriction which imposes 
a limit from four up to five observations (compounds) per 
descriptor or independent variable (Ferreira, 2002; Tava-
res, 2004) were respected in this approach and a maximum 
of four molecular descriptors per model was considered.
Statistical measures of significance including the 
LOO cross-validation coefficient (Q2), linear regression 
coefficient (r or r²), standard deviation (s), Fischer’s value 
(F) and standard predictive residual sum of squares value 
(sPRESS) were used to evaluate the robustness of the QSPR 
models. Moreover, a linear cross-correlation matrix of 
the descriptors was computed to verify if the independent 
variables were correlated to one another or otherwise. Pairs 
of descriptors which are highly correlated (R ≈ 1) to one 
another are deemed to provide nearly the same information 
to the model, while poorly correlated pairs of descriptors 
(R < 0.5) give distinct contribution to the model.
The differences between the experimental or ob-
served (logBBexp) and calculated or predicted (logBBpred) 
properties are called residual values. In this study, the 
compounds of the training set for which the absolute re-
sidual values exceeded two standard deviation (SD) from 
the mean of a model, were considered as outliers. This 
threshold corresponds to a significance level of ninety-five 
percent (Ferreira et al., 1999).
As mentioned previously, the seven compounds of 
the test set were not included in the build of the QSPR 
models, but were used to validate the best QSPR model 
constructed from the training set, and to evaluate its pre-
diction capacity. The predicted logBB value of each com-
pound in the test set was calculated using the equation of 
the best model by substitution of the molecular descriptors’ 
calculated values. The absolute residual values should not 
be higher than one SD from the mean of the model, which 
corresponds to a significance level of ninety-nine percent.
RESULTS AND DISCUSSION
Molecular descriptor selection
The proper selection of molecular descriptors, i.e., 
those truly relevant in describing the studied property or 
biological activity, is a challenge in QSPR/QSAR studies, 
since the amount of information generated by the available 
software is sometimes enormous and hard to comprehend 
(van de Waterbeemd, Rose, 2008). In this study, the cal-
culated molecular descriptors were related to lipophilicity 
(ClogP), intrinsic properties, such as molecular size and 
shape [volume (V), surface area] and electronic, topologic 
and mixed parameters [polarizability (α), number of H-bond 
acceptor and donor sites, polar surface area (PSA) and molar 
refractivity (MR)]. The polar surface area (PSA) calculation 
is defined as the sum of the surface of all the polar atoms of 
the molecule, especially N and O, including H atoms. The 
estimation of topological polar surface area (TPSA) was 
based on the method described by Ertl, 2000 (Ertl et al., 
2000). This method, implemented in MarvinBeans software 
(ChemAxon Ltd, 1998-2009), provides results which are 
practically identical to the 3D PSA, while the TPSA is ap-
proximately 100-times faster. Thus, the 2D representation 
is an approximation of the 3D PSA (Ertl, 2007).
As described in the Material and Methods Section, 
the scatter plots of logBB versus each of the calculated 
molecular descriptors were employed as preliminary 
selection criterion (data not shown). The most relevant 
independent variables, which were used to generate the 
QSPR models, presented a good dispersion of the data 
related to the variability of the biological property. Linear 
and non-linear tendencies were both considered. Only the 
number of H-bond acceptor and donor sites did not provide 
a suitable dispersion of data considering the variability of 
the logBB values and were therefore not included in the 
generation of the QSPR models.
2D-QSPR models
All the best fit models were linear given the ClogP 
values’ range was not larger than four logarithmic units. 
Thus, parabolic or bilinear functions were not considered 
(Patrick, 2008). The resulting 2D-QSPR models are listed 
below.
Model 1:
logBB = +0.47 (±0.11)ClogP – 0.94 (±0.30)
n = 21; r = 0.90 (r² = 0.81); s = 0.33; F = 80.04; Q2 = 0.74; 
sPRESS = 0.39 
Model 2: 
logBB = -0.02 (±0.01)PSA + 1.23 (±0.32)
n = 21; r = 0.89 (r² = 0.79); s = 0.35; F = 68.52; Q2 = 0.72; 
sPRESS = 0.40 
Model 3: 
logBB = +0.28 (±0.24)ClogP – 0.01 (±0.01)PSA – 0.03 
(±1.13)
n = 21; r = 0.91 (r² = 0.83); s = 0.32; F = 45.90; Q2 = 0.78; 
sPRESS = 0.38
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Model 4: 
logBB = +0.24 (±0.22)ClogP – 0.05 (±0.04)α – 0.01 
(±0.01)PSA + 1.76 (±1.92)
n = 21; r = 0.94 (r² = 0.88); s = 0.28; F = 39.74; Q2 = 0.82; 
sPRESS = 0.34
Model 5: 
logBB = +0.21 (±0.22)ClogP – 0.01 (±0.01)PSA – 0.03 
(±0.01)MR + 1.41 (±1.54)
 n = 21; r = 0.94 (r² = 0.88); s = 0.28; F = 42.10; Q2 = 0.83; 
sPRESS = 0.33
All the models presented r values higher than 0.8, 
indicating well fitting models. Models 4 and 5 had the 
highest r values (0.94; r² = 0.88) and the lowest s values 
(0.28). However, the s value is better evaluated when the 
dependent variable’s standard deviation is also given, 
and should be smaller than the latter (Patrick, 2008). For 
logBB, specifically, the standard deviation is not currently 
reported (Abraham et al., 2006).
The highest F values were obtained from models 1 
and 2 (80.04 and 68.52, respectively). It is noteworthy that 
the F value decreases as the number of descriptors in the 
model increases, indicating a substantial loss of statisti-
cal significance. This is likely due to the total number of 
compounds in the training set (n = 21).
The internal predictability of a model is expressed 
by the LOO cross-validation correlation coefficient (Q²), 
which is a very important statistical measure of QSPR/
QSAR models. The Q2 values for all models were higher 
than 0.5. Models 4 and 5 presented the highest Q² values 
(0.82 and 0.83, respectively).
Taking into account the evaluation of all statistical 
parameters measured, models 4 and 5 were considered 
the best QSPR models. Both equations presented three 
independent variables, but model 4 has α instead of MR. 
These two descriptors are indeed related to each other, 
since MR can express both steric and electronic effects. 
Hence, a linear cross-correlation matrix of the descriptors 
of models 4 and 5 was computed, using BuildQSAR® 
1.0.0, to verify if the independent variables were correlated 
to one another or otherwise (see Table III). As mentioned 
previously, pairs of descriptors that are highly correlated 
(R ≈ 1) to one another are deemed to provide nearly the 
same information to the model, while poorly correlated 
pairs of descriptors (R < 0.5) give distinct contribution to 
the model.
According to the results presented in Table 3, ClogP 
and PSA are highly correlated (R = 0.82), meaning they 
provide almost the same information to both models. Ho-
wever, this correlation value can be understood as a mathe-
matical artifact since the parameters are not biologically 
correlated (the former represents a lipophilic parameter, 
while the latter is a topological descriptor). Moreover, 
the models presenting both parameters proved to be sta-
tistically more significant, indicating the importance of 
including ClogP and PSA in the same model. Furthermore, 
a previous study reported poor intercorrelation between 
these two data items (R = 0.299) (Ertl, 2007) reinforcing 
the mathematical artifact assumption. On the other hand, 
the MR and α presented a high correlation coefficient (R 
= 0.84) and are actually correlated. MR is a composite 
parameter that considers molecular volume and polariza-
tion capacity, whereas α represents the relative tendency 
of a molecular charge distribution to be distorted from its 
normal shape by an external electric field, which may be 
caused by the presence of an ion or dipole nearby (Ertl, 
2007).
Therefore, models 4 and 5 have relevant indepen-
dent variables describing the logBB property. The signs 
of the regression coefficients indicate the direction of the 
descriptors’ contribution to the biological property. A po-
sitive sign can be interpreted as a favorable contribution 
to the biological property (ClogP) while a negative sign, 
as being unfavorable (PSA, α, MR).
Size and shape were not directly expressed in the 
2D-QSPR models. Instead, some descriptors such as 
MR and PSA consider molecule size or shape in their 
calculation. Molecular refractivity (MR), as mentioned 
earlier, for example, considers both molecular volume 
(and indirectly size and shape) and molecule polarizabi-
lity capability (Patrick, 2008). Polar surface area (PSA) is 
another example which considers topological parameters, 
taking into account the number of polar atoms (N, O and 
H) and is indirectly related to the size of the molecule 
(Ertl, 2007).
The internal predictability of models 4 and 5 was 
also explored as described in the Material and Methods 
section. The results are presented in Tables IV and V, 
respectively.
TABLE III - Linear cross-correlation matrix found for the 
molecular descriptors of models 4 and 5
ClogP α PSA MR
ClogP 1.00 0.06 0.82 0.26
α 1.00 0.03 0.84
PSA 1.00 0.20
MR 1.00
ClogP = calculated n-octanol/water partition coefficient; PSA = 
polar surface area; α = polarizability; MR = molar refractivity.
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TABLE IV - Residual values found for model 4
Compounds logBBexp logBBpred Residual Values (logBBexp – logBBpred)
1-OH-midazolam -0.07 0.06 -0.13
4-OH-midazolam -0.30 0.18 -0.48
alprazolam 0.04 0.17 -0.13
amitriptyline 0.98 1.06 -0.08
bretazenil -0.09 -0.43 0.34
clobazam 0.35 0.40 -0.05
desipramine 1.20 0.84 0.36
demethylclobazam 0.36 0.46 -0.10
demethyldiazepam 0.50 0.69 -0.19
diazepam 0.52 0.63 -0.11
flumazenil -0.29 -0.31 0.02
flunitrazepam 0.06 0.09 -0.03
Imipramine 0.83 0.92 -0.09
L663-581 -0.30 -0.46 0.16
M1L663-581 -1.34 -1.01 -0.33
M2L663-581 -1.82 -1.51 -0.32
mianserin 0.99 1.04 -0.05
midazolam 0.36 0.51 -0.15
oxazepam 0.61 0.40 0.21
Ro19-4603 -0.25 -0.69 0.44
triazolam 0.74 0.20 0.54
SD = 0.26; 2SD = 0.52
Note: logBBexp = logBB experimental or observed; logBBpred = logBB predicted or calculated; SD = standard deviation; 2SD = 
two standard deviations.
According to Tables 4 and 5, only model 4 proved 
capable of predicting logBB for all compounds of the 
training set. The absolute residual values did not exceed 
two SDs from the mean of model 4, meaning there were 
no outliers. Thus, model 4 was selected as the best 2D-
QSPR model.
External Validation
As outlined previously, model 4 was the best fit 
model selected to describe logBB in terms of ClogP, PSA 
and α. The external validation was performed using the 
test set (n = 7). The calculated molecular descriptors pre-
sent in model 4, the experimental and calculated logBB 
values, the respective residual values as well as the SD 
values obtained from the test set compounds, are listed 
in Table VI.
Six out of the seven test set compounds were well 
predicted by model 4, corresponding to good external 
predictability (85.7 %). The residual value of the molecu-
le ORG4428 was not considered statistically significant, 
since the difference was only in the second decimal. 
Moreover, the biological measurement of logBB is very 
susceptible to experimental errors.
The highest absolute residual value in the test set 
was observed for carbamazepine, which was the only 
molecule not well predicted by model 4. However, this 
drug penetration in the CNS is highly driven by several 
carriers, specifically the ABC family (ATP-binding casset-
te), such as the efflux protein P-gp (P-glycoprotein) (Sun et 
al., 2006). In addition, its pharmacokinetic profile is very 
complex due to its limited water solubility and capacity of 
self metabolism induction (Charney et al., 2006). Conse-
quently, carbamazepine’s BBB permeation is a composite 
of several mechanisms and the 2D-QSPR model proposed 
considers only passive crossing, resulting in differences 
between the experimental value (which considers all the 
mechanisms involved) and the predicted value.
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TABLE V - Residual values found for model 5
Compounds logBBexp logBBpred Residual Values (logBBexp – logBBpred)
1-OH-midazolam -0.07 -1.65 1.58
4-OH-midazolam -0.30 -1.53 1.23
alprazolam 0.04 -1.53 1.57
amitriptyline 0.98 -0.71 1.69
bretazenil -0.09 -2.23 2.14
clobazam 0.35 -0.89 1.24
desipramine 1.20 -0.54 1.74
demethylclobazam 0.36 -0.83 1.19
demethyldiazepam 0.50 -0.63 1.13
diazepam 0.52 -0.68 1.20
flumazenil -0.29 -1.84 1.55
flunitrazepam 0.06 -1.31 1.37
imipramine 0.83 -0.53 1.36
L663-581 -0.30 -2.51 2.21
M1L663-581 -1.34 -3.04 1.70
M2L663-581 -1.82 -3.52 1.70
mianserin 0.99 -0.35 1.34
midazolam 0.36 -1.22 1.58
oxazepam 0.61 -0.92 1.53
Ro19-4603 -0.25 -2.26 2.01
triazolam 0.74 -1.57 2.31
SD = 0.35; 2SD = 0.69
Note: logBBexp = logBB experimental or observed; logBBpred = logBB predicted or calculated; SD = standard deviation; 2SD = 
two standard deviations.
TABLE VI - Molecular descriptors of the best QSPR model (model 4), the experimental and calculated logBB values, the residual 
values and the respective SD value found for the test set compounds
Compounds ClogP PSA (Å²) α (Å³) logBBexp logBBpred Residual Values 
(logBBexp – logBBpred)
carbamazepine 3.22 46.33 26.95 0.00 0.72 -0.72
mirtazepine 3.38 19.37 31.23 0.53 0.82 -0.29
N-demethyldesipramine 3.24 29.26 30.98 1.06 0.70 0.36
ORG4428 2.49 32.70 34.11 0.82 0.33 0.49
ORG5222 3.10 12.47 29.83 1.03 0.89 0.14
ORG32104 2.25 41.49 32.26 0.52 0.27 0.25
ORG30526 2.74 21.26 27.99 0.39 0.81 -0.42
SD = 0.45
Note ClogP = calculated n-octanol/water partition coefficient; PSA = polar surface area; α = polarizability; logBBexp = logBB 
experimental or observed; logBBpred = logBB predicted or calculated; SD = standard deviation.
CONCLUSION
The present study employed a set of 21 molecu-
les to build 2D-QSPR models in order to predict BBB 
passive permeation, i.e., the mechanism proposed is the 
passive diffusion of the molecules through the BBB. The 
whole approach and methodology are simple and easy to 
interpret. Nevertheless, the models obtained were robust 
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and presented suitable internal predictability. The best fit 
model (model 4) had three descriptors, ClogP, PSA and α, 
which are well-known parameters and strongly influence 
BBB passive crossing. It is known that lipophilicity is a 
determining factor in drugs pharmacokinetics, influencing 
biological membrane permeation. The ClogP contribution 
to the models was positive in all the cases, suggesting that 
lipophilic moieties, that increase this parameter, facilitate 
passive translocation. By contrast, polar moieties seem 
to restrict molecule entry to the CNS. Quantitatively, this 
behavior is expressed by PSA and α, which contribute 
negatively to BBB diffusion. Published data has described 
linear models to explain the passive crossing through the 
BBB. The lipophilic characteristic has been described as 
the main factor that drives the passive diffusion from the 
blood into the cells and, in this case, the crossing through 
the BBB. As stated previously, the literature also reports 
other important parameters that seem to be related to 
the blood-brain partition (logBB): capability of forming 
hydrogen bonds, molecular flexibility, ability to bind to 
the lipophilic membrane, acid ionization constant (Ka and 
pKa), thermodynamic parameters (solvation energy, etc.), 
molecular refractivity (MR), molecular volume (V), polar 
surface area (PSA) and other electronic and topologic pa-
rameters. Nevertheless, the model presented in this study 
is comparable or better than other published 2D-QSAR 
BBB models and show similar descriptors used by other 
authors. (Norinder et al., 2002; Katritzky et al., 2006; van 
Damme et al., 2008; Iyer et al., 2002; Konovalov et al., 
2007; Subramanian et al., 2003; Zhao et al., 2007; Zhang 
et al., 2008; Narayanan et al., 2005; Young et al., 1988; 
Abraham, 2004; Goodwin et al., 2005). These findings can 
help future decisions about which groups are favorable or 
otherwise for CNS entry by BBB permeation, based on the 
physicochemical properties evaluated here. Additionally, 
due to its excellent external predictability, the best fit mo-
del can be applied to predict the logBB property of other 
compounds with the same structural motif, such as an aze-
pine or isosteric ring bound to at least one aromatic ring.
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